corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
Company profile
Ticker
LXRX
Exchange
Website
CEO
Lonnel Coats
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LEXICON GENETICS INC/TX, LEXICON PHARMACEUTICALS, INC./DE
SEC CIK
Corporate docs
Subsidiaries
Lexicon Pharmaceuticals (New Jersey), Inc. ...
IRS number
760474169
LXRX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Mar 24
DEFA14A
Additional proxy soliciting materials
26 Mar 24
DEF 14A
Definitive proxy
26 Mar 24
S-3
Shelf registration
25 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Material Modifications to Rights of Security Holders
12 Mar 24
PRE 14A
Preliminary proxy
11 Mar 24
8-K
Lexicon Pharmaceuticals Reports Fourth Quarter 2023
11 Mar 24
8-K
Entry into a Material Definitive Agreement
29 Dec 23
424B5
Prospectus supplement for primary offering
29 Dec 23
Transcripts
LXRX
Earnings call transcript
2023 Q3
8 Nov 23
LXRX
Earnings call transcript
2023 Q2
3 Aug 23
LXRX
Earnings call transcript
2023 Q1
2 May 23
LXRX
Earnings call transcript
2022 Q4
2 Mar 23
LXRX
Earnings call transcript
2022 Q3
10 Nov 22
LXRX
Earnings call transcript
2022 Q2
3 Aug 22
LXRX
Earnings call transcript
2022 Q1
5 May 22
LXRX
Earnings call transcript
2021 Q4
28 Feb 22
LXRX
Earnings call transcript
2021 Q3
4 Nov 21
LXRX
Earnings call transcript
2021 Q2
30 Jul 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.12 mm | 21.12 mm | 21.12 mm | 21.12 mm | 21.12 mm | 21.12 mm |
Cash burn (monthly) | 27.05 mm | (no burn) | 16.54 mm | 12.94 mm | 13.87 mm | 11.08 mm |
Cash used (since last report) | 179.01 mm | n/a | 109.47 mm | 85.63 mm | 91.80 mm | 73.29 mm |
Cash remaining | -157.89 mm | n/a | -88.36 mm | -64.52 mm | -70.68 mm | -52.18 mm |
Runway (months of cash) | -5.8 | n/a | -5.3 | -5.0 | -5.1 | -4.7 |
Institutional ownership, Q4 2023
55.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 1 |
Closed positions | 104 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 3.34 bn |
Total shares | 135.67 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Invus | 117.55 mm | $387.93 mm |
Biotechnology Value Fund L P | 16.15 mm | $0.00 |
Pinnacle Associates | 1.73 mm | $2.65 bn |
Compagnie Lombard Odier SCmA | 94.00 k | $143.82 mm |
SG Americas Securities | 43.79 k | $67.00 k |
KWB Wealth | 40.64 k | $62.18 mm |
Tiaa Trust, National Association | 27.00 k | $41.31 mm |
Chemistry Wealth Management | 12.00 k | $18.36 mm |
Raymond James & Associates | 10.84 k | $16.59 mm |
LifeSteps Financial | 10.00 k | $15.30 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Artal International S.C.A. | Series A Convertible Preferred Stock | Grant | Acquire A | Yes | No | 108.5 | 1,150,922 | 124.88 mm | 1,150,922 |
28 Feb 24 | Kristen Alexander | Common Stock | Payment of exercise | Dispose F | No | No | 2.62 | 11,793 | 30.90 k | 47,800 |
28 Feb 24 | Kristen Alexander | Common Stock | Option exercise | Acquire M | No | No | 0 | 15,927 | 0.00 | 59,593 |
28 Feb 24 | Kristen Alexander | Common Stock | Option exercise | Acquire M | No | No | 0 | 10,616 | 0.00 | 43,666 |
28 Feb 24 | Kristen Alexander | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,700 | 0.00 | 33,050 |
28 Feb 24 | Kristen Alexander | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 15,927 | 0.00 | 31,853 |
28 Feb 24 | Kristen Alexander | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 10,616 | 0.00 | 10,617 |
28 Feb 24 | Kristen Alexander | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,700 | 0.00 | 0 |
28 Feb 24 | Jeffrey L Wade | Common Stock | Payment of exercise | Dispose F | No | No | 2.62 | 37,691 | 98.75 k | 324,214 |
28 Feb 24 | Jeffrey L Wade | Common Stock | Option exercise | Acquire M | No | No | 0 | 49,113 | 0.00 | 361,905 |
News
Needham Reiterates Hold on Lexicon Pharmaceuticals
11 Apr 24
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
27 Mar 24
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
27 Mar 24
Lexicon Pharmaceuticals Announces Clinical Data On The Impact Of Sotagliflozin On Stroke And Heart Attack Risk Among Four Lexicon-Sponsored Presentations At The American College Of Cardiology 73rd Annual Scientific Session & Expo
25 Mar 24
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis Of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment In Patients With Type 1 Diabetes And Chronic Kidney Disease
12 Mar 24
Press releases
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
25 Mar 24
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?
13 Mar 24
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
11 Mar 24
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
11 Mar 24
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
11 Mar 24